Gland Pharma Limited has announced its updated schedule for analyst and institutional investor meetings, with a confirmed meeting scheduled for March 23, 2026. The pharmaceutical company submitted this intimation to both BSE Limited and National Stock Exchange of India Limited on March 18, 2026, in compliance with regulatory requirements.

Updated Meeting Schedule

The company has organized a focused engagement with the investment community, moving from the previously announced March 18-20 schedule to a specific confirmed meeting. The updated schedule provides clarity on the investor interaction program with confirmed participants.

Regulatory Compliance Framework

The intimation was filed pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates listed companies to inform stock exchanges about material events and investor interactions.

Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer, signed the official communication digitally on March 18, 2026. The document was addressed to both major Indian stock exchanges where the company's shares are listed.

Meeting Format and Flexibility

Gland Pharma has maintained that the meeting schedule remains subject to change. The company specifically noted that modifications may occur due to exigencies on the part of the investor, analyst, or the company itself. This flexibility clause ensures that all parties can accommodate any unforeseen circumstances that might affect the planned interactions.

The one-on-one meeting format with Ventura Securities allows for detailed discussions about the company's business performance, strategic initiatives, and market outlook. Such meetings are standard practice for listed companies to maintain regular communication with their investor base and analyst community.

Gland Pharma Limited has disclosed receiving a significant GST tax demand order from tax authorities for the financial year 2019-20. The pharmaceutical company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on March 06, 2026.

GST Demand Details

The Deputy Commissioner (ST)-V, GST Department, Telangana has issued an order demanding GST tax of INR 5,03,51,468 along with applicable interest and penalty of INR 1,25,87,867 under the provisions of the CGST Act, 2017, SGST Act, 2017 and IGST Act, 2017. The order dated March 05, 2026, was received by the company through email.

Grounds for GST Demand

The GST authority has raised the demand on two primary contentions:

• Levy of Tax on Export Turnover: INR 4,57,79,447 levied by treating export turnover as local sales
• Credit Notes Issue: INR 45,72,022 levied due to non-specified reasons on issue of certain credit notes pertaining to export turnover

Company's Response and Impact Assessment

Gland Pharma has stated that upon assessment of facts and prevailing law, the company believes the tax demand and penalties levied are not justified. The pharmaceutical manufacturer plans to file the necessary appeal with the appellate authority to contest the order.

Regarding the financial impact, the company has evaluated that there will be no material impact on its financials, operations, or other activities due to the said order. This assessment suggests the company's confidence in successfully challenging the GST demand through the appellate process.

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations, demonstrating the company's commitment to transparency with stakeholders regarding material developments that could potentially affect its operations or financial position.